Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Pragmatiston Apr 27, 2020 2:56am

227 Views

Post# 30956260

RE:RE:Will Trial Results Be Sufficiently Conclusive?

Results from the earlier trial tested 250 mg/day ATB 346 with 1500 mg/day Naproxen. WOMAC score for ATB was 4.5 day 4, and 7.6 day 10. This was based on a sample size of 12, and was compared with an average Naproxen score on 5. Not sure how one can compare a time depented score with an average score based on unstated time parameters. I have taken NSAIDs for years, and I am confident that a 50mg change in dosage would have minimal effect for me. If H2S is the game changer, then I would welcome it with open arms. Having been burned with ACAST and Oncolytics (try reading about them) I remain pragmatic.

I hope your optimism regrding ATE is realized with positive trial results.

Bullboard Posts

Changing Europe’s dependency on HREE from China